1
|
Maslakova AA, Golyshev SA, Potashnikova DM, Moisenovich AM, Orlovsky IV, Smirnova OV, Rubtsov MA. SERPINA1 long transcripts produce non-secretory alpha1-antitrypsin isoform: In vitro translation in living cells. Int J Biol Macromol 2023; 241:124433. [PMID: 37086761 DOI: 10.1016/j.ijbiomac.2023.124433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Revised: 03/24/2023] [Accepted: 03/27/2023] [Indexed: 04/24/2023]
Abstract
SERPINA1 is a well-studied serpin gene due to its dramatic impact on human health. Translation initiation at the main SERPINA1 start codon produces the only known alpha1-antitrypsin (AAT) isoform intended for secretion. AAT performs essential functions by inhibiting proteases and modulating immunity. However, SERPINA1 expression at the level of translation is not sufficiently studied. Here we hypothesize that the main SERPINA1 ORF can be alternatively translated, producing a non-secretory AAT isoform by either masking or excluding a signal peptide. We defined SERPINA1 long mRNA isoforms specific for prostate (DU145) and liver (HepG2) cell lines and studied their individual expression by in vitro assay. We found that all long transcripts produce both glycosylated secretory AAT-eGFP fusion protein and non-glycosylated intracellular AAT-eGFP (initiated from an alternative AUG-2 start codon), with the proportion regulated by the SERPINA1 5'-UTR. Both fusion proteins localize to distinct cellular compartments: in contrast to a fusion with the secretory AAT accumulating in the ER, the intracellular one exhibits nuclear-cytoplasmic shuttling. We detected putative endogenous AAT isoform enriching the nuclear speckles. CONCLUSION: Alternative translation initiation might be a mechanism through which SERPINA1 expands the biological diversity of its protein products. Our findings open up new prospects for the study of SERPINA1 gene expression.
Collapse
Affiliation(s)
- A A Maslakova
- Faculty of Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia.
| | - S A Golyshev
- A.N. Belozersky Institute of Physical and Chemical Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119992, Russia
| | - D M Potashnikova
- Faculty of Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia
| | - A M Moisenovich
- Faculty of Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia
| | - I V Orlovsky
- Research Institute of Molecular and Cellular Medicine, Рeoples' Friendship University of Russia (RUDN University), Miklukho-Maklaya, Moscow 117198, Russia
| | - O V Smirnova
- Faculty of Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia
| | - M A Rubtsov
- Faculty of Biology, M.V. Lomonosov Moscow State University, Leninskie Gory, Moscow 119991, Russia; Center for Industrial Technologies and Entrepreneurship, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya, Moscow 119991, Russia
| |
Collapse
|
7
|
Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA. Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. J Proteome Res 2008; 7:3146-58. [DOI: 10.1021/pr800060r] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Spiros D. Garbis
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Stavros I. Tyritzis
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Theodoros Roumeliotis
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Panagiotis Zerefos
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Eugenia G. Giannopoulou
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Antonia Vlahou
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Sophia Kossida
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Jose Diaz
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Stavros Vourekas
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Constantin Tamvakopoulos
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Kitty Pavlakis
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Despina Sanoudou
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| | - Constantinos A. Constantinides
- Biomedical Research Foundation, Academy of Athens, Greece, Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece, Department of Computer Science and Technology, University of Peloponnese, Tripoli, Greece, Department of Pathology, Institute for Drug Development, San Antonio, Texas, and Department of Pathology, Athens University Medical School, Greece
| |
Collapse
|
10
|
Mbeunkui F, Metge BJ, Shevde LA, Pannell LK. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 2007; 6:2993-3002. [PMID: 17608509 PMCID: PMC2584611 DOI: 10.1021/pr060629m] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Proteins secreted (the secretome) from cancer cells are potentially useful as biomarkers of the disease. Using LC-MS/MS, the secreted proteomes from a series of isogenic breast cancer cell lines varying in aggressiveness were analyzed by mass spectrometry: nontumorigenic MCF10A, premalignant/tumorigenic MCF10AT, tumorigenic/locally invasive MCF10 DCIS.com, and tumorigenic/metastatic MCF 10CA cl. D. Proteomes were obtained from conditioned serum-free media, partially fractionated using a small reverse phase C2 column, and digested with trypsin for analysis by LC-MS/MS, using a method previously shown to give highly enriched secreted proteomes (Mbeunkui et al. J. Proteome Res. 2006, 5, 899-906). The search files produced from five analyses (three separate preparations) were combined for database searching (Mascot) which produced a list of over 250 proteins from each cell line. The aim was to discover highly secreted proteins which changed significantly in abundance corresponding with aggressiveness. The most apparent changes were observed for alpha-1-antichymotrypsin and galectin-3-binding protein which were highly secreted proteins from MCF10 DCIS.com and MCF10CA cl. D, yet undetected in the MCF10A and MCF10AT cell lines. Other proteins showing increasing abundance in the more aggressive cell lines included alpha-1-antitrypsin, cathepsin D, and lysyl oxidase. The S100 proteins, often associated with metastasis, showed variable changes in abundance. While the cytosolic proteins were low (e.g., actin and tubulin), there was significant secretion of proteins often associated with the cytoplasm. These proteins were all predicted as products of nonclassical secretion (SecretomeP, Center for Biological Sequence Analysis). The LC-MS/MS results were verified for five selected proteins by western blot analysis, and the relevance of other significant proteins is discussed. Comparisons with two other aggressive breast cancer cell lines are included. The protein with consistent association with aggressiveness in all lines, and in unrelated cancer cells, was the galectin-3-binding protein which has been associated with breast, prostate, and colon cancer earlier, supporting the approach and findings. This analysis of an isogenic series of cell lines suggests the potential usefulness of the secretome for identifying prospective markers for the early detection and aggressiveness/progression of cancer.
Collapse
Affiliation(s)
| | | | - Lalita A. Shevde
- Joint submission by L. Pannell and L. Shevde, Mitchell Cancer Institute, Medical Sciences Building, Room 2015, University of South Alabama, 307 University Blvd, Mobile AL 36688. Tel: (251) 414-8201. Fax: (251) 414-8281. E-mail:
| | - Lewis K. Pannell
- Joint submission by L. Pannell and L. Shevde, Mitchell Cancer Institute, Medical Sciences Building, Room 2015, University of South Alabama, 307 University Blvd, Mobile AL 36688. Tel: (251) 414-8201. Fax: (251) 414-8281. E-mail:
| |
Collapse
|